Bloomberg Markets examines spread of multidrug-resistant bacteria in India, discusses global implications

NewsGuard 100/100 Score

Bloomberg Markets magazine in its June issue examines microbes that incorporate the New Delhi metallo-beta-lactamase-1, or NDM-1, gene, making them resistant to nearly all available antibiotics. The article focuses on India, where the gene is thought to have developed due to the widespread and uncontrolled use of antibiotics, but notes that cases of NDM-1 antibiotic-resistant bacteria have been documented in Canada, France, Italy, Kosovo, and South Africa, without patients having traveled to India. Bloomberg describes how the gene was discovered and named; how NDM-1 is affecting India's medical tourism industry; what the Indian government and health officials in the country and elsewhere are doing to fight multidrug-resistant bacteria; and how NDM-1 is spreading through the water and possibly food supply in India. "The number of countries reporting NDM-1 will continue to grow as more bacteria pick up the gene and people transport it around the globe," Bloomberg writes (Gale/Narayan, 5/7).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Leveraging CRISPR/Cas technology to address antimicrobial resistance